Education, Teaching, and Quality Improvement |

Efficacy of Levodropropizine in Adult and Children: A Meta-analysis of Published Studies FREE TO VIEW

Francesco De Blasio, MD; Luigi Lanata, MD; Peter Dicpinigaitis, MD; Federico Saibene, MD; Michela Bagnasco, MD; Alessandro Zanasi, MD; Giovanni Fontana, MD
Author and Funding Information

Dompè, Milano, Italy

Chest. 2013;144(4_MeetingAbstracts):523A. doi:10.1378/chest.1702702
Text Size: A A A
Published online


SESSION TITLE: Clinical Improvement Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: Cough in adults and children is amid the most common symptoms managed by healthcare professionals. In adults, usual causes are common airways infection, GERD, post nasal drip; in children acute cough is commonly due to URTI. Empiric treatment is often needed and mainly two classes of antitussives drugs are available: centrally acting (opioids and non opioids) and peripherally acting. Levodropropizine, is an orally-administered non-opiod agent whose peripheral antitussive action may result from its modulation of sensory neuropeptide levels within the respiratory tract. Levodropropizine is a very well tolerated peripheral drug, while central cough suppressants (opioids and non-opioids) may be associated with even serious adverse events, especially in children.

METHODS: A comprehensive systematic literature search was performed on main databases (PubMed/MEDLINE, EMBASE, and Cochrane Library) from their inception throughout January 2012, to identify original clinical studies of levodropropizine vs. control in adult and pediatric population. Overall, 7 studies including a total of 2633 patients met the eligibility criteria. Three studies were conducted vs. central antitussives (Banderali 1995, Kim Dong Soo 2002, and De Blasio 2012), and 1 study vs. placebo (Fiocchi 1991). We performed a meta-analysis with the aim to evaluate the overall efficacy of levodropropizine vs. control in adults and in children. In order to make the efficacy outcomes comparable, we standardized the variables of the different studies, particularly: cough severity, frequency of cough and nocturnal sleeping quality.

RESULTS: The results of our meta-analysis on both adult pediatric and studies, plotted in a meta-analytic chart, showed that the overall reduction of the severity of all efficacy parameters was higher in the levodropropizine group, and the difference vs. controls was highly statistically significant (P<0.01).

CONCLUSIONS: This standardized meta-analysis of published studies provides an overview of the major comparative evidence on levodropropizine in terms of efficacy in both adult and pediatric setting.

CLINICAL IMPLICATIONS: This standardized meta-analysis indicates that levodropropizine is an effective antitussive drug, showing better outcomes vs. central antitussive drugs in terms of reducing cough intensity, frequency and nightly awakenings.

DISCLOSURE: Francesco De Blasio: Consultant fee, speaker bureau, advisory committee, etc.: Consultant fee Luigi Lanata: Employee: Medical Director Federico Saibene: Employee: Junior Medical Manager Michela Bagnasco: Employee: Medical Manager The following authors have nothing to disclose: Peter Dicpinigaitis, Alessandro Zanasi, Giovanni Fontana

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543